公开(公告)号：US20170355781A1

公开(公告)日：2017-12-14

申请号：US15683087

申请日：2017-08-22

Applicant: CCAM BIOTHERAPEUTICS LTD.

Inventor： Gal MARKEL ,  Tehila BEN MOSHE ,  Yair SAPIR ,  Ilana MANDEL ,  Jacob SCHACHTER ,  Rona ORTENBERG

IPC: C07K16/42 ,  A61K39/395 ,  C07K16/30 ,  A61K35/17 ,  A61K45/06 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/42 ,  A61K35/17 ,  A61K39/39566 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3007 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/686

Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

公开(公告)号：US20170044270A1

公开(公告)日：2017-02-16

申请号：US15306664

申请日：2015-04-27

Applicant: CCAM BIOTHERAPEUTICS LTD.

Inventor： Tehila BEN-MOSHE ,  Yair SAPIR ,  Ilana MANDEL ,  Gal MARKEL ,  Jacob SCHACHTER ,  Rona ORTENBERG ,  Francis Joseph CARR ,  Robert George E. HOLGATE ,  Timothy David JONES

IPC: C07K16/30 ,  G01N33/574 ,  C07K16/28 ,  A61K35/17 ,  A61K39/395 ,  A61K45/06

Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Abstract translation: 提供能够特异性结合含有非CDR区域中的人到鼠反向突变的人CEACAM1分子的人源化抗体及其编码多核苷酸序列。 还提供了包含这些抗体的药物组合物及其用于治疗和诊断癌症和其它病症的方法。

公开(公告)号：US20170166637A1

公开(公告)日：2017-06-15

申请号：US15039022

申请日：2014-11-25

Applicant: CCAM BIOTHERAPEUTICS LTD.

Inventor： Tehila BEN-MOSHE ,  Yair SAPIR ,  Ilana MANDEL ,  Edna MEILIN

IPC: C07K16/28 ,  A61K39/395 ,  A61K35/17

CPC classification number: C07K16/2803 ,  A61K35/17 ,  A61K39/39558 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.